Thomas A.Briggs (Tom)

Partner

(T) + 1.858.314.1164

Tom Briggs' practice is focused on transactions where intellectual property, technology, information, and data assets are the driving force for the deal. He has particular experience in global and cross-border licensing, development, strategic alliances, joint ventures, mergers, acquisitions, divestitures, and IP-related settlement agreements.

Tom negotiates and drafts agreements involving the creation, transfer, use, and sharing of intellectual property, including agreements relating to research, development, licensing, strategic alliances, joint ventures, clinical trials, supply, manufacturing, distribution, co-promotion, confidentiality, noncompetition, consulting, assignment, digital health, and information technology. He also oversees and evaluates due diligence relating to the acquisition or licensing of technology and intellectual property. Tom conducts seminars on IP and technology transaction subjects in public and private settings, including for legal education credits.

Tom serves clients in many industries, particularly pharmaceuticals, biotechnology, health care, food, renewable energy, semiconductors, software, steel, and chemicals. These clients include Athersys, Bunge, Celgene, EagleTree Capital, Genomatica, HUYABio, Idemitsu Kosan, Incyte, ISK Animal Health, Kirin, P&G, Takeda, and Toolgen.

In helping clients with their technology transactions, Tom draws upon a rare combination of work experiences. He is a patent lawyer who has litigated cases involving infringement, misappropriation, and noncompetition and has prosecuted patent and trademark registrations. He has served as chief intellectual property officer and assistant general counsel of M.A. Hanna Company (now PolyOne Corporation). He also spent 10 years as a practicing chemical engineer and plant supervisor with Union Carbide/Praxair before his career as a lawyer.

Experience

  • Airtech acquires Champion Valves Inc. and Valve & Pump Specialties, Inc.Jones Day advised Airtech Group, a portfolio company of EagleTree Capital, L.P., in connection with the acquisition and related financing of Champion Valves Inc. and Valve & Pump Specialties, Inc., a designer, assembler, and distributor of industrial check valves and butterfly valves.
  • Incyte grants license to and collaborates with Zai Lab to develop and commercialize anti-PD1 pharmaceutical products in ChinaJones Day represented Incyte Corporation in its sublicense out to Zai Lab Limited of certain intellectual property rights to an anti-PD1 molecule licensed to Incyte from MacroGenics, Inc. globally in 2017 and which Incyte is actively developing in the U.S. and other jurisdictions outside of China.
  • AbbVie acquires MavupharmaJones Day advised AbbVie Inc. in its acquisition of Seattle-based Mavupharma, a privately held biopharmaceutical company focused on novel approaches to target the STING (STimulator of INterferon Genes) pathway for the treatment of cancer.
  • Genomatica enters sponsored research agreement relating to biofuels, acquires technology from REGIJones Day represented Genomatica, Inc. in entering a sponsored research agreement for the development of advanced biofuels and acted as special IP counsel to Genomatica in its simultaneous acquisition of the assets of the life sciences division of Renewable Energy Group, Inc. ("REGI").
  • Incyte enters strategic collaboration agreement with Innovent for three clinical pharmaceuticals in ChinaJones Day represented Incyte Pharmaceuticals in its strategic collaboration and license agreement with Innovent Biologics for the regulatory development and commercialization in China of three clinical stage pharmaceutical candidates, a FGFR1/2/3 inhibitor, a JAK1 inhibitor, and a PI3K delta inhibitor, for treatment of hematological and oncological diseases.
  • Procter & Gamble acquires consumer health business of Merck KGaAJones Day advised The Procter & Gamble Company (“P&G”) in its €3.375 billion ($4.2 billion) acquisition of the worldwide consumer health business of Merck KGaA.
  • Sanofi and Denali Therapeutics collaborate to develop treatments for neurological and inflammatory diseasesJones Day represented Sanofi in its strategic collaboration and license agreement with Denali Therapeutics for the development, manufacturing, and commercialization of many pre-clinical and clinical candidates for treatment of certain neurological and systemic inflammatory diseases, including those known to target RIPK1, such as MS, Alzheimer's Disease and ALS, and rheumatoid arthritis.
  • EagleTree Capital acquires majority interest of Gaylord Chemical Company, LLCJones Day advised EagleTree Capital in its acquisition of a majority interest in and related financing of Gaylord Chemical Company, LLC, a specialty chemical producer.
  • EagleTree Capital acquires majority stake in FuseFXJones Day advised EagleTree Capital in connection with the acquisition of a majority stake in and related financing of FuseFX, LLC, a visual effects studio providing visual effects services for episodic television, feature films, commercials, and VR productions.
  • Georgia-Pacific sells European nonwovens business to Glatfelter for $185 millionJones Day advised Georgia-Pacific LLC ("GP") in the sale of its European nonwovens business to Glatfelter, a global manufacturer of specialty papers and engineered products, for $185 million.
  • Big Red acquired by Keurig Dr PepperJones Day advised Big Red Group Holdings, LLC in the acquisition by Keurig Dr Pepper Inc. ("KDP") of all the outstanding membership interests of Big Red not already owned by KDP.
  • Patrón Tequila acquired by BacardiJones Day advised Patrón Spirits International AG ("Patrón") in connection with the acquisition by Bacardi Limited of all of the issued and outstanding shares of Patrón.
  • The Carlyle Group sells Signode Industrial Group Holdings to Crown Holdings, Inc. for $4 billionJones Day advised The Carlyle Group and its affiliates in connection with the sale of Signode Industrial Group Holdings (Bermuda) Ltd., a leading global provider of transit packaging systems and solutions, to Crown Holdings, Inc., a worldwide leader in the design, manufacture and sale of packaging products for consumer goods, for an aggregate purchase price of up to $4 billion.
  • NXP acquires OmniPHYJones Day advised NXP Semiconductors N.V. in its acquisition of OmniPHY, a provider of automotive Ethernet subsystem technology.
  • Athersys receives $21 million equity investment by HEALIOSJones Day represented Athersys, Inc., an international biotechnology company developing novel and proprietary best-in-class therapies designed to extend and enhance the quality of human life, in connection with a $21 million equity investment by HEALIOS K.K., a developer of treatments for retinal diseases and age-related macular degeneration using cell technology.
  • EagleTree Capital acquires Airtech GroupJones Day advised EagleTree Capital in its acquisition of a majority stake in and related financing of Airtech Group, a provider of specialized pressure technologies.
  • EagleTree Capital acquires CORSAIR for $525 millionJones Day advised EagleTree Capital in connection with the acquisition and related financing of CORSAIR, a world leader in high-performance PC components, gaming peripherals, and enthusiast memory, from Francisco Partners for $525 million.
  • Procter & Gamble sells incontinence brand in Spain and Portugal to Paul Hartmann AGJones Day advised The Procter & Gamble Company in the sale of its 'Lindor' adult incontinence brand in Spain and Portugal to Paul Hartmann AG, a supplier of medical and hygiene products.
  • EagleTree Capital portfolio company acquires hotel investment event portfolio from Burba Hotel NetworkJones Day advised EagleTree Capital (formerly Wasserstein Partners) in connection with the acquisition and related financing by portfolio company Northstar Travel Group, a leading provider of business-to-business information, content, events, data, research, custom content, and software dedicated to the global travel and meeting industries, of the hotel investment event portfolio from Burba Hotel Network, the American Hotel & Lodging Association, and their other partners.
  • Takeda acquires Ariad Pharmaceuticals for $5.2 billionJones Day advised Takeda Pharmaceuticals U.S.A., Inc. on intellectual property matters relating to its $5.2 billion acquisition of Ariad Pharmaceuticals.
  • Speaking Engagements

    • November 7, 2018
      Licensing Fundamentals for Business Executives and Startups
    • May 6, 2015
      Licensing Fundamentals - for Business Executives and Startups, CONNECT Frameworks Workshop
    • May 7, 2014
      Licensing Fundamentals - for Business Executives and Startups, CONNECT Frameworks Workshop
    • November 6, 2013
      Technology Transfer: Adapting Models for BioInspired Success given at the San Diego Zoo's 4th Annual BioInspiration Conference
    • February 7, 2013
      Licensing Fundamentals for Business Executives and Startups, a CONNECT Frameworks Workshop
    • February 2, 2012
      Licensing Fundamentals for Business Executives and Startups
    • January 19, 2011
      Licensing Fundamentals for Business Executives and Startups
    • December 14, 2010
      Partnering Transactions for IP Development and Commercialization
    • August 12, 2010
      Licensing for Business Development Executives and Non-Licensing Attorneys
    • June 3, 2010
      Licensing Essentials Business Executives and Startups in the Life Sciences and Software Industries, a CONNECT Frameworks Workshop
    • January 20, 2010
      Licensing Essentials for Business Executives and Startups
    • January 14, 2010
      Transactions for Exploiting IP: Strategic Alternatives to M&A, Jones Day University
    • October 20, 2009
      Contentious IP Provisions in M&A and Licensing Transactions and Related Trends, CLE presentation
    • August 12, 2009
      Patents 101, Licensing and Exhaustion, CLE presentation
    • August 6, 2009
      The Latest on Current Big Ticket IP Issues: Obviousness and Patent Licensing/Exhaustion, ACCA San Diego Chapter, CLE presentation
    • June 10, 2009
      Fundamentals of Licensing Transactions - for Business Executives and Startups, CONNECT Frameworks Seminar
    • December 9, 2008
      Licensing Transactions in Life Sciences and Software for Business Executives, CONNECT Frameworks Seminar
    • February 5, 2008
      Fundamentals of Licensing in the Life Sciences, CONNECT Frameworks Seminar
    • February 15, 2007
      Fundamentals of Licensing in the Life Sciences, CONNECT Frameworks Seminar
    • December 11, 2006
      Advanced IP Support of M&A and Private Equity Transactions, CLE presentation
    • June 26, 2006
      Patents and Trade Secrets in the Food Industry, Annual Meeting of the Institute of Food Technologists
    • June 22, 2006
      World Class IP Practices: Management, Prosecution and Enforcement, CLE presentation
    • July 22, 2004
      Patents, Trade Secrets and Trademarks, CLE Presentation
    • February 25, 2004
      IP Licensing: Tips for the Taiwanese Semiconductor Industry, Taiwan Semiconductor Industry Association at the Industrial Technology Research Institute in the Science and Industrial Park
    • September 30, 2003
      IP Licensing: Tips for the Taiwan Semiconductor Industry, Taiwan Semiconductor Industry Association and ITRI
    • May 16, 2003
      Strategic Alternatives to Acquisitions, The 2003 Institute for Business Lawyers and Corporate Counsel
    • October 1, 2002
      IP and Technology Management, Taiwan Semiconductor Industry Association and National Taiwan University College of Law
    • November 12, 2001
      Learning from the Mistakes of the 90's, Tips on Licensing To and From Financially Troubled Companies
    We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.